| Name | Title | Contact Details |
|---|
Oral Surgery Partners is a practice management company that provides professional management services for leading oral diagnostic and surgical practices for any issues that affect the mouth, teeth, and facial region.
Essentia Health is an integrated health system serving patients in Minnesota, North Dakota, Wisconsin and Idaho. In the summer of 2010, Essentia Health brought together the operations of SMDC Health System, Brainerd Lakes Health, Innovis Health, Essentia Community Hospitals and Clinics, and the Essentia Institute of Rural Health. Essentia Health was originally formed in January 2004 through a partnership of the Benedictine Health System and SMDC Health System. In January 2008, Innovis Health joined Essentia Health and all of the hospitals and clinics owned by the Benedictine Health System were transferred to Essentia Community Hospitals and Clinics.
Babeskin Bodycare is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Golden Years Medical Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.